CJC-1295 with DAC 5mg*10vials
-
Detail
CJC-1295 with DAC 5mg
Long-Acting GHRH Analog | DAC Technology for Extended Half-Life Research
Drug Affinity Complex Conjugate · Albumin-Binding Design · Research Use Only
🔗 DAC Albumin Binding
The Drug Affinity Complex covalently bonds to serum albumin after administration, extending half-life from minutes to approximately 6–8 days.
🧬 GHRH Axis Action
Acts on pituitary GHRH receptors to stimulate the body's own growth-hormone release — a pulse-preserving approach to GH-axis research.
🛡 DPP-IV Resistant
Four stabilizing substitutions at positions 2, 8, 15 and 27 protect against the rapid DPP-IV cleavage that limits native GHRH.
🤝 Classic Pairing
Frequently studied alongside ipamorelin — the GHRP pathway — for dual-pathway growth-axis research designs.
Product Overview
CJC-1295 with DAC (also known as DAC:GRF, drug affinity complex:growth hormone-releasing factor) is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). Its core is the 29-amino-acid GRF(1-29) sequence carrying four stabilizing substitutions, conjugated to a proprietary Drug Affinity Complex (DAC) at the C-terminus — the modification that gives this version of the compound its defining pharmacokinetic property.
Native GHRH has a plasma half-life of only about 7 minutes, limited by rapid DPP-IV cleavage. CJC-1295 solves this twice over: the four amino-acid substitutions resist enzymatic degradation, and the DAC moiety forms a covalent bond with serum albumin after administration, effectively borrowing albumin's long circulation time. The result is a half-life of approximately 6–8 days in published human pharmacokinetic data — supporting infrequent dosing schedules in research protocols, in contrast to short-acting analogs such as CJC-1295 without DAC (modified GRF 1-29).
Each vial contains 5mg of high-purity CJC-1295 with DAC as a lyophilized powder, supplied for research use only.
Specifications
Product Name CJC-1295 with DAC (DAC:GRF) Synonyms DAC:GRF · Drug Affinity Complex GRF · Long-Acting GHRH Analog CAS Number 863288-34-0 Core Peptide Sequence GRF(1-29) analog with four stabilizing substitutions at positions 2, 8, 15 and 27; DAC conjugated via a C-terminal lysine residue Molecular Weight ≈ 3647 g/mol (including DAC moiety) Net Content 5 mg / vial Appearance White to off-white lyophilized powder Purity ≥ 99% (by HPLC) Solubility Soluble in water / aqueous buffer Storage Store at 2–8°C; for long-term storage, freeze and protect from light and moisture What the DAC Actually Does
Drug Affinity Complex (DAC) is a half-life-extension platform technology. After administration, the DAC moiety reacts with the free thiol group of cysteine-34 on serum albumin, forming a stable covalent bond. Because albumin circulates for weeks and is protected from renal clearance by its size, the conjugated peptide effectively "borrows" albumin's pharmacokinetic profile.
This is why CJC-1295 with DAC reaches a half-life of roughly 6–8 days in human pharmacokinetic studies — long enough to support once-weekly research dosing — while the unmodified core peptide alone would be cleared within minutes to tens of minutes.
Mechanism of Action
Step What Happens 1. Albumin Conjugation The DAC moiety forms a covalent bond with serum albumin, creating a circulating depot of the GHRH analog. 2. GHRH-Receptor Activation The GRF(1-29) core binds GHRH receptors on pituitary somatotroph cells with high affinity. 3. Endogenous GH Release Pituitary growth-hormone synthesis and secretion are stimulated through the body's own axis — rather than administering exogenous GH directly. 4. Sustained Exposure The albumin-linked depot maintains low-level GHRH-receptor engagement for days, producing a prolonged GH/IGF-1 axis signal in research models. With DAC vs No DAC: Two Distinct Products
Aspect CJC-1295 with DAC (this product) CJC-1295 No DAC (Modified GRF 1-29) Core Sequence Same GRF(1-29) analog with the same four substitutions Identical core sequence Albumin-Binding DAC Yes — covalent albumin conjugation No DAC attached Half-Life (Published Data) ≈ 6–8 days ≈ 30 minutes Dosing Frequency (Research Protocols) Infrequent — weekly-scale schedules Multiple administrations per day common GH Release Pattern Sustained low-level axis engagement Discrete pulses per administration Research Highlights
📖 Teichert et al., 2005 (J Clin Pharmacol) — Human PK/PD
First-in-human pharmacokinetic/pharmacodynamic evaluation of the long-acting GHRH analog CJC-1295 in healthy volunteers: dose-dependent increases in growth-hormone levels with a half-life in the 6–8 day range — one of the few human-data points for this compound.
📖 DAC Platform Technology
The albumin-binding Drug Affinity Complex is documented across long-acting peptide-analog development, with CJC-1295 among the best-known applications (reviewed in "Long-acting growth hormone analogues," Springer, 2011).
📖 Growth-Axis Combination Research
CJC-1295 is widely referenced in growth-axis research alongside ipamorelin — a ghrelin-receptor (GHRP) agonist acting through a complementary pathway — for studies of dual-pathway GH regulation.
Research Applications & Compliance Notes
🧬 Growth-hormone-axis pharmacology — GHRH-receptor activation and GH/IGF-1 signaling studies. ⏱ Half-life-extension platform research — albumin-conjugation pharmacokinetics. 🤝 Combination studies with ghrelin-receptor agonists (e.g., ipamorelin) for dual-pathway designs. 📋 Comparative studies of sustained-release vs pulse-based GH-secretagogue profiles. Compliance note: CJC-1295 (both forms) is prohibited by WADA as a growth-hormone-releasing substance, and is listed on doping-control prohibited lists in multiple jurisdictions. Buyers conducting sports-related research should factor this in.
Reconstitution & Handling
💧 Add sterile or bacteriostatic water slowly down the side of the vial; swirl gently until fully dissolved — do not shake vigorously. 🧪 Aliquot reconstituted solution to avoid repeated freeze-thaw cycles. 🧊 Lyophilized powder: store frozen (-20°C), protected from light and moisture; reconstituted solution: refrigerate and use within your validated stability window. ⚖️ Handle with aseptic technique and appropriate PPE per your laboratory SOP. Quality Assurance
✔ Lot-specific Certificate of Analysis: HPLC purity confirmation + mass-spectrometry identity verification (confirming the DAC conjugate).
✔ Third-party batch testing documentation available upon request.
References & Further Reading
- Teichert L, Kenter R, et al. Pharmacokinetic/pharmacodynamic evaluation of the long-acting growth hormone releasing hormone analogue CJC-1295 in healthy volunteers. J Clin Pharmacol. 2005;45(8):891-899.
- Long-acting growth hormone analogues (Drug Affinity Complex technology). In: Growth Hormone Related Proteins, Springer Protocols. 2011.
- Trends in peptide drug discovery — GHRH analogs and half-life-extension strategies. Nat Rev Drug Discov. 2021.
- CJC-1295 — Wikipedia / PubChem CID 56841945 (CAS 863288-34-0 reference).
- Targeting growth hormone function: strategies and therapeutic applications. Signal Transduct Target Ther. 2019.
Disclaimer: This product is intended exclusively for in-vitro laboratory research use. It is not approved for human or animal use, is not a drug, food, cosmetic, or dietary supplement, and is not intended to diagnose, treat, cure or prevent any disease. All products are supplied strictly for research purposes only. -
Customer ReviewsNo comments